With paltusotine, we’re developing a once-daily pill for acromegaly that may replace the life-disrupting process of getting an injection every month or needing to follow a strict daily schedule for short-acting octreotide. Soon entering Phase 3, a once-daily oral therapy will be a welcome development for patients and could solve for a real market need. And there’s plenty more where that came from. Read on for our latest advancements and the market opportunities they hold for investment in our focused area of endocrinology pharmaceuticals.
Events
Jan 13, 2021 from 4:30 PM to 5:10 PM EST
Dec 3, 2020 from 1:00 PM to 1:45 PM EST
Dec 1 - Dec 3, 2020
Press Releases
January 6, 2021
Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference
Scott Struthers, Ph.D., Founder & CEO of Crinetics, will present a company update on Wednesday, January 13th at 1:30 pm Pacific Time. A live audio webcast of Dr. Struthers’ presentation may be accessed on the Events section of the company’s website or directly on the J.P. Morgan virtual meeting platform.
November 23, 2020
Crinetics Pharmaceuticals to Participate in December Investor Conferences
Crinetics management, including Dr. Scott Struthers and Dr. Alan Krasner, will participate in the upcoming Evercore ISI 3rd Annual HealthCONx Conference and the Piper Sandler 32nd Annual Healthcare Conference in December.
Dive deeper into Crinetics, the market needs we address, our pipeline and candidate drugs, clinical trials, and more.
Investor Resources
Data Provided by Refinitiv. Minimum 15 minutes delayed.